Cancer Research Cancer Health Disparities Conference 2009 SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Hare, T.
Right arrow Articles by Druker, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Hare, T.
Right arrow Articles by Druker, B. J.
[Cancer Research 65, 4500-4505, June 1, 2005]
© 2005 American Association for Cancer Research

Priority Reports

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Thomas O'Hare1, Denise K. Walters1, Eric P. Stoffregen2, Taiping Jia2, Paul W. Manley4, Jürgen Mestan4, Sandra W. Cowan-Jacob4, Francis Y. Lee5, Michael C. Heinrich3, Michael W.N. Deininger2 and Brian J. Druker1,2

1 Howard Hughes Medical Institute and 2 Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute; 3 Portland Veterans Affairs Medical Center, Portland, Oregon; 4 Novartis Institutes for Biomedical Research, Basel, Switzerland; and 5 Bristol-Myers Squibb Oncology, Princeton, New Jersey

Requests for reprints: Thomas O'Hare, Howard Hughes Medical Institute, Oregon Health and Science University, L592, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239. Phone: 503-494-5596; Fax: 503-494-3688; E-mail: oharet{at}ohsu.edu.

Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired imatinib resistance has been traced to Bcr-Abl kinase domain mutations with decreased imatinib sensitivity. Thus, alternate Bcr-Abl kinase inhibitors that have activity against imatinib-resistant mutants would be useful for patients who relapse on imatinib therapy. Two such Bcr-Abl inhibitors are currently being evaluated in clinical trials: the improved potency, selective Abl inhibitor AMN107 and the highly potent dual Src/Abl inhibitor BMS-354825. In the current article, we compared imatinib, AMN107, and BMS-354825 in cellular and biochemical assays against a panel of 16 kinase domain mutants representing >90% of clinical isolates. We report that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for all imatinib-resistant mutants tested, with the exception of T315I. Thus, both inhibitors hold promise for treating imatinib-refractory CML.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
H. Konig, M. Copland, S. Chu, R. Jove, T. L. Holyoake, and R. Bhatia
Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
Cancer Res., December 1, 2008; 68(23): 9624 - 9633.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
G. Dai, M. Pfister, A. Blackwood-Chirchir, and A. Roy
Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia
J. Clin. Pharmacol., November 1, 2008; 48(11): 1254 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Porkka, P. Koskenvesa, T. Lundan, J. Rimpilainen, S. Mustjoki, R. Smykla, R. Wild, R. Luo, M. Arnan, B. Brethon, et al.
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Blood, August 15, 2008; 112(4): 1005 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, and S. Grant
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Blood, August 1, 2008; 112(3): 793 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Quintas-Cardama and J. Cortes
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
Clin. Cancer Res., July 15, 2008; 14(14): 4392 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Wu, F. Meng, L.-Y. Kong, Z. Peng, Y. Ying, W. G. Bornmann, B. G. Darnay, B. Lamothe, H. Sun, M. Talpaz, et al.
Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
J Natl Cancer Inst, July 2, 2008; 100(13): 926 - 939.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. J. Christopher, D. Cui, W. Li, A. Barros Jr., V. K. Arora, H. Zhang, L. Wang, D. Zhang, J. A. Manning, K. He, et al.
Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys
Drug Metab. Dispos., July 1, 2008; 36(7): 1341 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. J. Christopher, D. Cui, C. Wu, R. Luo, J. A. Manning, S. J. Bonacorsi, M. Lago, A. Allentoff, F. Y. F. Lee, B. McCann, et al.
Metabolism and Disposition of Dasatinib after Oral Administration to Humans
Drug Metab. Dispos., July 1, 2008; 36(7): 1357 - 1364.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. P. Shah, H. M. Kantarjian, D.-W. Kim, D. Rea, P. E. Dorlhiac-Llacer, J. H. Milone, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, A. Charbonnier, et al.
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
J. Clin. Oncol., July 1, 2008; 26(19): 3204 - 3212.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. W. Deininger
Nilotinib
Clin. Cancer Res., July 1, 2008; 14(13): 4027 - 4031.
[Full Text] [PDF]

Home page
 BloodHome page
E. Jabbour, H. Kantarjian, D. Jones, M. Breeden, G. Garcia-Manero, S. O'Brien, F. Ravandi, G. Borthakur, and J. Cortes
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
Blood, July 1, 2008; 112(1): 53 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. K. Hiwase, V. Saunders, D. Hewett, A. Frede, S. Zrim, P. Dang, L. Eadie, L. B. To, J. Melo, S. Kumar, et al.
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Clin. Cancer Res., June 15, 2008; 14(12): 3881 - 3888.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Verstovsek, A. Tefferi, J. Cortes, S. O'Brien, G. Garcia-Manero, A. Pardanani, C. Akin, S. Faderl, T. Manshouri, D. Thomas, et al.
Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Clin. Cancer Res., June 15, 2008; 14(12): 3906 - 3915.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
I. Samudio, S. Kurinna, P. Ruvolo, B. Korchin, H. Kantarjian, M. Beran, K. Dunner Jr., S. Kondo, M. Andreeff, and M. Konopleva
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells
Mol. Cancer Ther., May 1, 2008; 7(5): 1130 - 1139.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. La Rosee, S. Holm-Eriksen, H. Konig, N. Hartel, T. Ernst, J. Debatin, M. C. Mueller, P. Erben, A. Binckebanck, L. Wunderle, et al.
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib
Haematologica, May 1, 2008; 93(5): 765 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Trowe, S. Boukouvala, K. Calkins, R. E. Cutler Jr., R. Fong, R. Funke, S. B. Gendreau, Y. D. Kim, N. Miller, J. R. Woolfrey, et al.
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
Clin. Cancer Res., April 15, 2008; 14(8): 2465 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gontarewicz, S. Balabanov, G. Keller, R. Colombo, A. Graziano, E. Pesenti, D. Benten, C. Bokemeyer, W. Fiedler, J. Moll, et al.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Blood, April 15, 2008; 111(8): 4355 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, et al.
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
PNAS, April 8, 2008; 105(14): 5507 - 5512.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
L. K. Kenealy, C. B. Christenson, and C. B. Williams
Current Therapies for Chronic Myeloid Leukemia
Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Godin-Heymann, L. Ulkus, B. W. Brannigan, U. McDermott, J. Lamb, S. Maheswaran, J. Settleman, and D. A. Haber
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
Mol. Cancer Ther., April 1, 2008; 7(4): 874 - 879.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist, April 1, 2008; 13(4): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Carayol, E. Katsoulidis, A. Sassano, J. K. Altman, B. J. Druker, and L. C. Platanias
Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway
J. Biol. Chem., March 28, 2008; 283(13): 8601 - 8610.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Fojo
Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better
Oncologist, March 1, 2008; 13(3): 277 - 283.
[Full Text] [PDF]

Home page
 BloodHome page
J. S. Khorashad, D. Milojkovic, P. Mehta, M. Anand, S. Ghorashian, A. G. Reid, V. De Melo, A. Babb, H. de Lavallade, E. Olavarria, et al.
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
Blood, February 15, 2008; 111(4): 2378 - 2381.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. le Coutre, O. G. Ottmann, F. Giles, D.-W. Kim, J. Cortes, N. Gattermann, J. F. Apperley, R. A. Larson, E. Abruzzese, S. G. O'Brien, et al.
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
Blood, February 15, 2008; 111(4): 1834 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Blood, February 15, 2008; 111(4): 1774 - 1780.
[Full Text] [PDF]

Home page
 haematolHome page
M. Baccarani, F. Pane, and G. Saglio
Monitoring treatment of chronic myeloid leukemia
Haematologica, February 1, 2008; 93(2): 161 - 169.
[Full Text] [PDF]

Home page
 BloodHome page
J. Cortes, E. Jabbour, H. Kantarjian, C. C. Yin, J. Shan, S. O'Brien, G. Garcia-Manero, F. Giles, M. Breeden, N. Reeves, et al.
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Blood, December 1, 2007; 110(12): 4005 - 4011.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. M. Kantarjian, F. Giles, N. Gattermann, K. Bhalla, G. Alimena, F. Palandri, G. J. Ossenkoppele, F.-E. Nicolini, S. G. O'Brien, M. Litzow, et al.
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Blood, November 15, 2007; 110(10): 3540 - 3546.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. A. Larson, G. Rege-Cambrin, J. Radich, A. Hochhaus, A. M. Apanovitch, et al.
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Blood, October 1, 2007; 110(7): 2309 - 2315.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. O'Hare, C. A. Eide, and M. W. N. Deininger
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Blood, October 1, 2007; 110(7): 2242 - 2249.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Rahmani, T. K. Nguyen, P. Dent, and S. Grant
The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation
Mol. Pharmacol., September 1, 2007; 72(3): 788 - 795.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. Hantschel, U. Rix, U. Schmidt, T. Burckstummer, M. Kneidinger, G. Schutze, J. Colinge, K. L. Bennett, W. Ellmeier, P. Valent, et al.
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
PNAS, August 14, 2007; 104(33): 13283 - 13288.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. A. Schiffer
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Dasmahapatra, N. Yerram, Y. Dai, P. Dent, and S. Grant
Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation
Clin. Cancer Res., July 15, 2007; 13(14): 4280 - 4290.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Pfeifer, B. Wassmann, A. Pavlova, L. Wunderle, J. Oldenburg, A. Binckebanck, T. Lange, A. Hochhaus, S. Wystub, P. Bruck, et al.
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Blood, July 15, 2007; 110(2): 727 - 734.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Ray, S. W. Cowan-Jacob, P. W. Manley, J. Mestan, and J. D. Griffin
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Blood, June 1, 2007; 109(11): 5011 - 5015.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Guilhot, J. Apperley, D.-W. Kim, E. O. Bullorsky, M. Baccarani, G. J. Roboz, S. Amadori, C. A. de Souza, J. H. Lipton, A. Hochhaus, et al.
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Blood, May 15, 2007; 109(10): 4143 - 4150.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
J Natl Cancer Inst, May 2, 2007; 99(9): 680 - 693.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. G. Jorgensen, E. K. Allan, N. E. Jordanides, J. C. Mountford, and T. L. Holyoake
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Blood, May 1, 2007; 109(9): 4016 - 4019.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Cortes, P. Rousselot, D.-W. Kim, E. Ritchie, N. Hamerschlak, S. Coutre, A. Hochhaus, F. Guilhot, G. Saglio, J. Apperley, et al.
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Blood, April 15, 2007; 109(8): 3207 - 3213.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Nam, A. Williams, A. Vultur, A. List, K. Bhalla, D. Smith, F. Y. Lee, and R. Jove
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
Mol. Cancer Ther., April 1, 2007; 6(4): 1400 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hochhaus, H. M. Kantarjian, M. Baccarani, J. H. Lipton, J. F. Apperley, B. J. Druker, T. Facon, S. L. Goldberg, F. Cervantes, D. Niederwieser, et al.
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Blood, March 15, 2007; 109(6): 2303 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
S. Soverini, S. Colarossi, A. Gnani, F. Castagnetti, G. Rosti, C. Bosi, S. Paolini, M. Rondoni, P. P. Piccaluga, F. Palandri, et al.
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Haematologica, March 1, 2007; 92(3): 401 - 404.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Weisberg, L. Catley, R. D. Wright, D. Moreno, L. Banerji, A. Ray, P. W. Manley, J. Mestan, D. Fabbro, J. Jiang, et al.
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias
Blood, March 1, 2007; 109(5): 2112 - 2120.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes
Important Therapeutic Targets in Chronic Myelogenous Leukemia
Clin. Cancer Res., February 15, 2007; 13(4): 1089 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Quintas-Cardama, H. Kantarjian, D. Jones, C. Nicaise, S. O'Brien, F. Giles, M. Talpaz, and J. Cortes
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
Blood, January 15, 2007; 109(2): 497 - 499.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
N. P. Shah
Medical Management of CML
Hematology, January 1, 2007; 2007(1): 371 - 375.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology, January 1, 2007; 2007(1): 376 - 383.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. A. Thomas
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges
Hematology, January 1, 2007; 2007(1): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Ann Intern Med, December 19, 2006; 145(12): 913 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al.
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
Clin. Cancer Res., December 1, 2006; 12(23): 7180 - 7186.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Soverini, G. Martinelli, S. Colarossi, A. Gnani, F. Castagnetti, G. Rosti, C. Bosi, S. Paolini, M. Rondoni, P. P. Piccaluga, et al.
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia
J. Clin. Oncol., November 20, 2006; 24(33): e51 - e52.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Fiskus, M. Pranpat, M. Balasis, P. Bali, V. Estrella, S. Kumaraswamy, R. Rao, K. Rocha, B. Herger, F. Lee, et al.
Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate-Sensitive or Imatinib Mesylate-Resistant Chronic Myelogenous Leukemia Cells.
Clin. Cancer Res., October 1, 2006; 12(19): 5869 - 5878.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker, and M. W. Deininger
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations
Blood, October 1, 2006; 108(7): 2332 - 2338.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood, September 15, 2006; 108(6): 1809 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Jabbour, J. Cortes, H. M. Kantarjian, S. Giralt, D. Jones, R. Jones, F. Giles, B. S. Andersson, R. Champlin, and M. de Lima
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
Blood, August 15, 2006; 108(4): 1421 - 1423.
[Abstract] [Full Text] [PDF]
<